Drug Trial Radar · NCT04676646
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
366
Actual
Start
Mar 8, 2021
Primary completion
Jul 15, 2024
Study completion Jul 15, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue therapy for hyperkalaemia (HK).
Conditions
- Hyperkalaemia
- Heart Failure With Reduced Ejection Fraction
Interventions
Sodium zirconium cyclosilicateDrug
Investigational medicinal product
PlaceboDrug
Placebo comparator
SpironolactoneOther
Background intervention. During the run-in phase, spironolactone will be initiated/uptitrated up to a maximum of 50 mg per day. During the randomized withdrawal phase the spironolactone dose at the end of the run-in phase will be maintained.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Who Achieved Response, Defined as Serum Potassium (sK+) Within 3.5 to 5.0 mEq/L, Spironolactone Greater Than or Equal to 25 mg Daily, no Rescue Therapy for HyperkalaemiaTime frame: From Month 1 (Visit 9) to Month 6 (Visit 14), up to 6 months
Locations
89 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Fairhope, Alabama
Research Site
Los Angeles, California
Research Site
Torrance, California
Research Site
Evanston, Illinois
Research Site
Hazel Crest, Illinois
Research Site
Oak Lawn, Illinois
Research Site
Kansas City, Missouri
Research Site
New York, New York
Research Site
Winston-Salem, North Carolina
Research Site
Greenville, South Carolina
Research Site
Houston, Texas
Research Site
Falls Church, Virginia
Research Site
Belo Horizonte, Brazil
Research Site
Bragança Paulista, Brazil
Research Site
Brasília, Brazil
Research Site
Brasília, Brazil
Research Site
Campina Grande do Sul, Brazil
Research Site
Campinas, Brazil
Research Site
Canoas, Brazil
Research Site
Joinville, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
Salvador, Brazil
Research Site
Santa Cruz do Sul, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Votuporanga, Brazil
Research Site
Cambridge, Ontario, Canada
Research Site
Kitchener, Ontario, Canada
Research Site
Scarborough Village, Ontario, Canada
Research Site
Scarborough Village, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Whitby, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.